ImmunoGen, Inc. (NASDAQ:IMGN) Q4 2018 Earnings Conference Call Transcript
Feb 08, 2019 • 08:00 am ET
Good day, and welcome to the Immunogen Fourth Quarter 2018 and Year End Results Conference Call. Today's conference is being recorded.
At this time, I would like to turn the call over to Ms. Courtney O'Konek. Please go ahead.
Good morning. (Technical Difficulty) today's call. Earlier today, we issued a press release that includes a summary of our recent progress and fourth quarter and full year 2018 operating results. This press release and a recording of this call can be found under the Investors and Media section of our website at immunogen.com.
On the call today are Mark Enyedy, our president and CEO and Anna Berkenblit, our Chief Medical Officer. Rich Gregory, our Chief Scientific Officer; Glen McKee, our Chief Business Officer; and Dave Foster, our Chief Accounting Officer will join the team for Q&A.
During today's call, we will highlight key accomplishments with the business over the last twelve months, review our fourth quarter and year-end financial results and discuss upcoming milestones. During the discussions, we will use forward-looking statements and our actual results may differ materially from such statements. Descriptions of the risks and uncertainties associated with an investment in ImmunoGen are included in our SEC filings.
And with that, I'll now turn the call over to Mark.
Thanks, Courtney. Good morning, everyone, and thank you for joining us today. 2018 was another year of rapid execution and significant progress for Immunogen, led by the completion of enrollment in FORWARD I, our registration study for mirvetuximab and platinum-resistant ovarian cancer, the presentation of combination data in over a 100 patients to support label expansion for this program, and the advancement of our earlier-stage portfolio.
With the benefit of this performance, we enter 2019 poised to deliver on a number of important catalysts, including top line results from FORWARD I in the first half of the year, potentially BLA and MAA submissions for mirvetuximab monotherapy in the second half of the year, additional data from combination studies with mirvetuximab and from expansion studies in AML and BPDCN for our programs targeting hematological malignancies, and filing an IND for our next development program, IMGC936, before the end of the year.
We also come into the year with a strong balance sheet and a proven management team that brings deep experience in oncology development and commercialization to deliver on the business. This combination of assets and capabilities positions us well to execute on our strategy and generate significant value in the coming year.
As a reminder, we've set four strategic priorities for the Company: first, complete the development and launch mirvetuximab in 2020 for the treatment of women with platinum-resistant ovarian cancer; second, accelerate our IGN programs in hematological malignancies; next, build upon our leadership position in ADCs through continued platform innovation; and finally, expand the reach of that innovation and maintain financial strength through high value partnerships.
Over the last 12 months, we've made significant progress towards each of these objectives. For mirvetuximab, we successfully completed a pre-specified interim futility analysis